Andamertinib is an investigational new drug that is being develop by Avistone Biotechnology Co., Ltd. for the treatment of non-small-cell lung cancer (NSCLC). It is an epidermal growth factor receptor (EGFR) antagonist.
Andamertinib is an irreversible EGFR inhibitor designed to target EGFR with exon 20 insertion mutations.
Clinical trials
The following clinical trials are evaluating andamertinib for treating NSCLC: phase 2 (on going) phase 2 (on going) in combination wth vebreltinib or osimertinib phase 3 (recruiting) in combination with vebreltinib or pemetrexed plus carboplatin or cisplatin
References